Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00073944 · ClinicalTrials.gov registry record · Phase 1

BCX-1777 in Treating Patients With Refractory Cancer

A Phase 1 study of Cancer, sponsored by BioCryst Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00073944: Completed Phase 1 study of Cancer, sponsored by BioCryst Pharmaceuticals.

NCT00073944 is a Phase 1 study of Cancer that has completed, run by BioCryst Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00073944, a Phase 1 study of Cancer, has completed, sponsored by BioCryst Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.

Conditions Studied

Cancer

Interventions

  • DRUG forodesine hydrochloride

Study Locations (1)

Ohio

  • Cleveland Clinic Taussig Cancer Center - Cleveland

Trial Details

FieldValue
Start Date 2003-04
Phase Phase 1
BioCryst Pharmaceuticals

29 total trials

What the finished NCT00073944 record still lists

NCT00073944 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which forodesine hydrochloride is the first listed.

NCT00073944 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00073944 about?

NCT00073944 is a clinical study titled "BCX-1777 in Treating Patients With Refractory Cancer". RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.

What is the current status of trial NCT00073944?

This trial is currently completed. It is a Phase 1 study. The study started on 2003-04.

What conditions does trial NCT00073944 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT00073944?

The interventions under investigation include: forodesine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00073944?

This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00073944 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00073944, the US trial registry maintained by the National Library of Medicine. NCT00073944 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.